Performance status and smoking status are independent favorable prognostic factors for survival in non-small cell lung cancer: A comprehensive analysis of 26,957 patients with NSCLC

Journal of Thoracic Oncology

Volumn 5, Issue 5, 2010, Pages 620-630

  Kawaguchi, Tomoya ^a   Takada, Minoru ^a   Kubo, Akihito ^a   Matsumura, Akihide ^a   Fukai, Shimao ^b   Tamura, Atsuhisa ^c   Saito, Ryusei ^d   Maruyama, Yosihito ^e   Kawahara, Masaaki ^a   Ignatius Ou, Sai Hong ^f  

^a NATIONAL HOSPITAL ORGANIZATION KINKI CHUO CHEST MEDICAL CENTER   (Japan)

^b Department of Cardiovascular Surgery   (Japan)

^c TOKYO NATIONAL HOSPITAL   (Japan)

^d Shibukawa Medical Center   (Japan)

^e Osaka Prefecture University   (Japan)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cancer registry; Gender; Histology; National Hospital Study Group for Lung Cancer (NHSGLC); Non small cell lung cancer; Prognostic factors; Smoking status; WHO performance status

Indexed keywords

DOCETAXEL; GEFITINIB;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER MORTALITY; CANCER SURGERY; CANCER SURVIVAL; FEMALE; HISTOLOGY; HUMAN; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PERFORMANCE; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SMOKING; WORLD HEALTH ORGANIZATION;

EID: 77951880386     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181d2dcd9     Document Type: Article

References (25)

1. Rami-Porta R, Ball D, Crowley J, et al. The IASLC lung cancer staging project: proposals for the revision of the T descriptors in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol 2007;2:593-602. (Pubitemid 47171780)
2. Rusch VW, Crowley J, Giroux DJ, et al. The IASLC lung cancer staging project: proposals or the revision of the N descriptors in the forthcoming seventh edition of the TNM classification for lung cancer. J Thorac Oncol 2007;2:603-612. (Pubitemid 47171781)
3. Postmus PE, Brambilla E, Chansky K, et al. The IASLC lung cancer staging project: proposals for revision of the M descriptors in the forthcoming (seventh) edition of the TNM classification of lung cancer. J Thorac Oncol 2007;2:686-693. (Pubitemid 47357520)
4. Goldstraw P, Crowley J, Chansky K, et al. The IASLC lung cancer staging project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol 2007;2:706-714. (Pubitemid 47357522)
5. Groome PA, Bolejack V, Crowley JJ, et al. The IASLC lung cancer staging project: validation of the proposals for revision of the T, N, and M descriptors and consequent stage grouping in the forth coming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol 2007;2:694-705.
6. Ou S-HI, Zell JA. Validation study of the proposed IASLC staging revisions of the T4 and M non-small cell lung cancer descriptors using data from 23,583 patients in the California Cancer Registry. J Thorac Oncol 2008;3:216-227.
7. Sculier J-P, Chansky K, Crowley J, et al. The impact of additional prognostic factors on survival and their relationship with the anatomical extent of disease expressed by the 6th edition of the TNM classification of malignant tumors and the proposals for the 7th edition. J Thorac Oncol 2008;3:457-466.
8. Chansky K, Sculier J-P, Crowley J, et al. The IASLC lung cancer staging project: prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer. J Thorac Oncol 2009;4:792-801.
9. Baser S, Shannon VR, Eapen GA, et al. Smoking cessation after diagnosis of lung cancer is associated with a beneficial effect on performance status. Chest 2006;130:1784-1790.
10. Tammemagi CM, Neslund-Dudas C, Simoff M, et al. Smoking and lung cancer survival: the role of comorbidity and treatment. Chest 2004;125: 27-37.
11. Kawaguchi T, Tamura A, Saito R, et al. Japanese ethnicity as compared to Caucasian ethnicity and never-smoking status are independent favorable prognostic factors for overall survival in non-small-cell lung cancer. A Collaborative Epidemiologic Study of the National Hospital Organization (NHO) Study Group for Lung Cancer in Japan and a Southern California Regional Cancer Registry. Presented at IASLC Meeting, San Francisco, CA, August 1, 2009. J Thorac Oncol 2009;4(Suppl 1):S425.
12. Sun S, Schiller JH, Gazdar AF. Lung cancer in never smokers-a different disease. Nature 2007;7:778-790.
13. Brundage MD, Davies D, Mackillop WJ. Prognostic factors in non-small cell lung cancer. Chest 2002;122:1037-1057.
14. Kawai H, Tada A, Kawahara M, et al. Smoking history before surgery and prognosis in patients with stage IA non-small-cell lung cancer-a multicenter study. Lung Cancer 2005;49:63-70.
15. Kawaguchi T, Matsumura A, Iuchi K, et al. Second primary cancers in patients with stage III non-small cell lung cancer successfully treated with chemo-radiotherapy. Jpn J Clin Oncol 2006;36:7-11.
16. Altundag O, Stewart DJ, Fossella FV, et al. Many patients 80 years and older with advanced non-small cell lung cancer (NSCLC) can tolerate chemotherapy. J Thorac Oncol 2007;2:141-146.
17. Albain KS, Crowley JJ, LeBlanc M, et al. Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol 1991;9:1618-1626.
18. Radzikowska E, Glaz P, Roszkowski K. Lung cancer in women: age, smoking, histology, performance status, stage, initial treatment and survival. Population-based study of 20 561 cases. Ann Oncol 2002;13: 1087-1093.
19. Lilenbaum RC, Cashy J, Hensing TA, et al. Prevalence of poor performance status in lung cancer patients. Implications for research. J Thorac Oncol 2008;3:125-129.
20. Dajczman E, Kasymjanova G, Kreisman H, et al. Should patient-rated performance status affect treatment decisions in advanced lung cancer? J Thorac Oncol 2008;3:1133-1136.
21. Lilenbaum RC, Herndon JE 2nd, List MA, et al. Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730). J Clin Oncol 2005;23:190-196.
22. Lilenbaum R, Axelrod R, Thomas S, et al. Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-smallcell lung cancer and a performance status of 2. J Clin Oncol 2008;26: 863-869.
23. Langer CJ, O'Byrne KJ, Socinski MA, et al. Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naive advanced non-small cell lung cancer. J Thorac Oncol 2008;3:623-630.
24. Buccheri G, Ferrigno D, Tamburini M. Karnofsky and ECOG performance status scoring in lung cancer: a prospective, longitudinal study of 536 patients from a single institution. Eur J Cancer 1996;32A:1135-1141.
25. Mok TS, Leong S, Liu X, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-957.